Testing a new treatment approach for relapsing multiple sclerosis

Plain-English translation of NCT05877963 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing , a medication that works by targeting immune cells that attack the nervous system in relapsing multiple sclerosis. The study is evaluating whether a new dosing schedule of this medication is safe and effective at reducing the number of active lesions seen on brain MRI scans. Researchers are also including a group of people who didn't have good results with similar medications in the past to see if the treatment works better for them.

Current treatments for relapsing multiple sclerosis help many people, but some patients don't respond well enough or experience side effects. This trial is exploring whether a modified approach to giving this medication might work better, offer fewer side effects, or help people who haven't done well on similar treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsing multiple sclerosis according to current diagnostic guidelines
your disease has been stable for at least 30 days before starting the study
your disability score is 5.5 or lower on the standard neurological scale
you are either new to multiple sclerosis treatment, or you stopped a previous treatment and waited the required time before enrolling
if you are a woman who can become pregnant, you are willing to use reliable birth control during the study and for 6 months after your last dose

You likely don't qualify if…

you have had a serious allergic or infusion reaction to similar immune-targeting medications in the past
you have primary progressive multiple sclerosis or inactive secondary progressive multiple sclerosis
you have chronic infections (such as active tuberculosis, chronic hepatitis B or C, or chronic urinary tract infections) that require ongoing treatment
you have a history of a serious opportunistic infection or progressive brain infection
you received a live vaccine (such as varicella or measles vaccine) within 4 weeks before starting the study

What participation looks like

Participants will receive infusions of the medication at scheduled visits over several months, with the dosing pattern varying slightly depending on which part of the study they join. You'll have MRI brain scans and blood tests at various timepoints to measure how well the treatment is working and monitor your safety. The study also includes a special group for people who didn't have good results with similar medications—they would stop their current treatment (following a required washout period) and then receive the new medication schedule to see if it works better for them.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(47 sites)

United States

TG Therapeutics Investigational Trial Site, Birmingham, Alabama

TG Therapeutics Investigational Trial Site, Cullman, Alabama

TG Therapeutics Investigational Trial Site, Orange, California

TG Investigational Site, Fort Collins, Colorado

TG Therapeutics Investigational Trial Site, Washington D.C., District of Columbia